HomeHealthUp to Rs 50 lakh per patient is provided for treatment of...

Up to Rs 50 lakh per patient is provided for treatment of rare diseases: Centre

New Delhi, Aug 9 (IANS) Up to Rs. 50 lakh per patient has been provided for treatment of rare diseases, said Anupriya Singh Patel, Union Minister of State for Health and Family Welfare, in a written reply in the Lok Sabha on Friday.

The National Policy for Rare Diseases (NPRD) was launched by the Ministry of Health and Family Welfare in March 2021.

Since then, “a total of 1,118 patients have benefited,” Patel informed.

“The financial support of up to Rs. 50 lakh per patient is provided for the treatment at the notified centres of excellence (CoEs) for rare diseases,” the minister added.

Based on the recommendation of the Central Technical Committee for Rare Diseases (CTCRD), presently 63 rare diseases are included under NPRD, Patel said.

There are also 12 CoEs, where patients can register themselves to avail the financial assistance.

The CoEs include premier Government tertiary hospitals that come with facilities for the diagnosis, prevention, and treatment of rare diseases.

There are about 7,000 known rare diseases, affecting around 8 per cent of the world’s population. About 75 per cent of rare disease patients happen to be children.

The NPRD identifies and categorises rare diseases into 3 groups: disorders that can be controlled to one-time curative treatment; those that require long-term/lifelong treatment with a relatively lower cost of treatment; and those that need definitive treatment but challenges are to make an optimal patient selection for benefit, very high cost, and lifelong therapy.

“The Ministry of Health and Family Welfare has obtained exemption from the Department of Expenditure on Goods & Services Tax (GST) and Basic Customs Duty on drugs imported for Rare Diseases for individual use and through CoE,” Patel said.

Further, she informed that a National Consortium for Research and Development on Therapeutics for Rare Diseases (NCRDTRD) has also been established to streamline research activities for rare diseases.

–IANS

rvt/

Go to Source

Disclaimer

The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.

Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.

Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.

For any legal details or query please visit original source link given with news or click on Go to Source.

Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.

If you are not willing to accept this disclaimer then we recommend reading news post in its original language.

RELATED ARTICLES
- Advertisment -

Most Popular